Anacor Pharmaceuticals, Inc. (ANAC) Tops Q2 EPS by 5c

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) reported Q2 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.93 million versus the consensus estimate of $3.03 million.

For earnings history and earnings-related data on Anacor Pharmaceuticals, Inc. (ANAC) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Ascendis Pharma (ASND) Tops Q2 EPS by 132c
• Studio City International Holdings Limited (MSC) Reports Q2 Loss of $0.02